Search results for "Elba"

showing 10 items of 25 documents

Towards a long-term dataset of ELBARA-II measurements assisting SMOS level-3 land product and algorithm validation at the Valencia Anchor Station

2015

[EN] The Soil Moisture and Ocean Salinity (SMOS) mission was launched on 2nd November 2009 with the objective of providing global estimations of soil moisture and sea salinity. The main activity of the Valencia Anchor Station (VAS) is currently to assist in a long-term validation of SMOS land products. This study focus on a level 3 SMOS data validation with in situ measurements carried out in the period 2010-2012 over the VAS. ELBARA-II radiometer is placed in the VAS area, observing a vineyard field considered as representative of a major proportion of an area of 50×50 km, enough to cover a SMOS footprint. Brightness temperatures (TB) acquired by ELBARA-II have been compared to those obser…

010504 meteorology & atmospheric sciencesMeteorologyGeography Planning and Development0211 other engineering and technologiesData validationlcsh:G1-92202 engineering and technology01 natural sciencesVineyardSoil roughnessFootprintEarth and Planetary Sciences (miscellaneous)Vegetation optical depth14. Life underwaterPrecipitationWater content021101 geological & geomatics engineering0105 earth and related environmental sciencesRadiometerHumedad del suelobrightness temperature ELBARA-II L-MEB SMOS SMOS level 3 data soil moisture soil roughness Valencia Anchor Station vegetation optical depth15. Life on landEspesor óptico de la vegetaciónTerm (time)GeographyL-MEB13. Climate actionBrightness temperatureRugosidad del sueloTemperatura de brilloSoil moistureBrightness temperaturelcsh:Geography (General)
researchProduct

Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance‐associated substitutions

2020

Background&aims The presence of baseline resistance-associated substitutions (RASs) reduced sustained virologic response (SVR) rates in chronic hepatitis C virus (HCV) genotype 1a infected patients treated with Elbasvir/Grazoprevir (EBR/GZR). This study aimed to evaluate the frequency of NS5A RASs and treatment outcomes in patients for whom EBR/GZR was intended. Methods We sequenced NS5A in 832 samples from German genotype1a-infected DAA-naive patients population-based, which were collected in the European Resistance Database. Treatment outcomes and clinical parameters were evaluated in 519 of these patients retrospectively. Results Overall, 6.5% of patients harbored EBR-specific NS5A RASs …

medicine.medical_specialtyElbasvirHepatologybusiness.industryHepatitis C virusTreatment outcomemedicine.disease_causeGastroenterology03 medical and health sciences0302 clinical medicineGenotype 1bGrazoprevir030220 oncology & carcinogenesisInternal medicineHepatitis C virus genotypeMedicine030211 gastroenterology & hepatologyIn patientbusinessNS5ALiver International
researchProduct

La expansión geográfica de la renta del tabaco

2007

El monopolio real del tabaco fue decretado sólo para la Corona de Castilla en 1636. Debido a su reconocida eficacia, los gobernantes españoles intentaron implantarlo allá donde fuese políticamente posible. Después de la guerra de Sucesión, fue establecido en la Corona de Aragón, ya que estos territorios perdieron entonces su régimen foral de autonomía. Como las provincias vascas y Navarra consiguieron conservar su régimen foral, el Gobierno español no pudo someter allí el régimen general del estanco tabaquero y tuvo que contentarse con negociar soluciones que no perjudicasen al estanco general. Finalmente, en el contexto de las reformas borbónicas en América, la Renta del Tabaco fue gradual…

Monopolios fiscalesCataloniaBalearesAmérica virreal españolaTax monopoliesHumanidadesBasque CountrySardiniaHistoriaPaís VascoNavarraBalearic IslandsNavarreCataluñaTobaccoLongónSpanish Royal TreasuryUNESCO::HISTORIA::Historia moderna:Historia [Materias Investigacion]:HISTORIA::Historia moderna [UNESCO]Colonial Spanish AmericaReal HaciendaAragonAragónTabacoValenciaCerdeñaElba
researchProduct

Estimation of volume fraction and gravimetric moisture of winter wheat based on microwave attenuation: a field scale study

2019

A considerable amount of water can be stored in vegetation, especially in regions experiencing large quantities of precipitation (mid-latitudes). In this context, an accurate estimate of the actual water status of the vegetation could lead to an improved understanding of the effect of plant water on the water budget. In this study, we developed and validated a novel approach to retrieve the vegetation volume fraction (δ) (i.e., volume percentage of solid plant material of a canopy in air) and the gravimetric vegetation water content (m g ) (i.e., amount of water per wet biomass) for winter wheat. The estimation was based on the attenuation of L-band microwave measurements through vegetation…

Canopy010504 meteorology & atmospheric sciencesMoistureAttenuation0211 other engineering and technologiesplant moistureContext (language use)Soil scienceVegetation water Content02 engineering and technologyVegetation01 natural sciencesSelhausenJülichvolume fractionVolume fractionGravimetric analysisEnvironmental sciencepassive microwavesPrecipitationRadiometerELBARA021101 geological & geomatics engineering0105 earth and related environmental sciencesagriculture
researchProduct

Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience.

2021

INTRODUCTION: We assessed the performance of direct-acting antivirals (DAAs) in hepatitis C virus (HCV)-infected people who use drugs (PWUDs) in terms of sustained virological response (SVR) and adherence rates in comparison to a location-matched cohort of non-PWUD HCV patients. METHODS: All consecutive HCV RNA-positive PWUDs were enrolled between 2015 and 2019. All subjects underwent DAA treatment according to international guidelines and then followed, at least, up to 12 weeks after the end of treatment (SVR12). The SVR and adherence to treatment was compared with that of non-PWUD HCV patients observed at hepatological units of the CLEO platform. Intention-to-treat analysis was performed.…

AdultMaleElbasvirmedicine.medical_specialtySofosbuvirSustained Virologic ResponseIntention to Treat AnalysiSubstance-Related DisordersHepatitis C virusmedicine.disease_causeAntiviral AgentsMedication Adherence03 medical and health sciences0302 clinical medicineRetrospective StudieInternal medicinemedicineHumansProspective StudiesRetrospective StudiesAntiviral AgentHepatologybusiness.industryGastroenterologyvirus diseasesGlecaprevirOdds ratioHepatitis C ChronicMiddle AgedSubstance-Related DisorderPibrentasvirdigestive system diseasesIntention to Treat AnalysisProspective StudieGrazoprevirItaly030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatologyFemalebusinessmedicine.drugHumanThe American journal of gastroenterology
researchProduct

Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM.

2020

Abstract Background In Europe, increases in HCV infection have been observed over the last two decades in MSM, making them a key population for recently acquired HCV. Alternative combinations of direct-acting antiviral agents against early HCV infection need to be assessed. Patients and methods In this pilot trial, MSM with recently acquired genotype 1 or 4 HCV infection were prospectively included and received 8 weeks of oral grazoprevir 100 mg and elbasvir 50 mg in a fixed-dose combination administered once daily. The primary endpoint was sustained virological response evaluated 12 weeks after the end of treatment (EOT) (SVR12). Secondary endpoints were the virological characterization of…

hepatitis C virusCyclopropanesMaleadverse eventmen who have sex with menHepacivirusmedicine.disease_causeSexual and Gender Minoritiesblood HIV RNA0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesfollow-upClinical endpointMedicinePharmacology (medical)infections030212 general & internal medicinehepatitis ceducation.field_of_studySulfonamideshepatitis c rnaImidazolesvirus diseasesHepatitis Cvirologyhepatitis C virus genotype 13. Good healthEuropeInfectious DiseasesGrazoprevirRNA Viral030211 gastroenterology & hepatologyDrug Therapy CombinationMicrobiology (medical)medicine.medical_specialtyElbasvirGenotypeHepatitis C virusPopulationelbasvirAntiviral Agentsreinfection03 medical and health sciencesInternal medicineQuinoxalinesHumansHomosexuality MaleAdverse effecteducationplasmasuicideBenzofuransPharmacologybusiness.industrySurrogate endpointHIVgrazoprevirHepatitis C Chronicmedicine.diseaseAmidessurrogate endpoints[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyQuality of LifeCarbamatesbusinessThe Journal of antimicrobial chemotherapy
researchProduct

The NMDA receptor complex: a promising target for novel antiepileptic strategies.

2001

Antiepileptic drugs (AEDs) cover a broad spectrum of pathological conditions ranging from seizures following congenital or acquired brain disorders to behavioural and psychiatric disorders and recently neuropathic pain. The need for novel antiepileptics raises from the expanding field of indications as well as from the fact, that special seizure types are refractory to common AEDs. In addition, many of the conventional antiepileptic drugs exhibit an unfavourable side-effect profile. Since there is growing evidence, that NMDA receptor activation might play a crucial role in epilepsy, NMDA receptor antagonists have become compounds of interest in preventing and treating seizures. This review …

N-Methylaspartatemedicine.medical_treatmentPharmacologyBiochemistryReceptors N-Methyl-D-AspartateFelbamatechemistry.chemical_compoundEpilepsyDrug DiscoveryIfenprodilmedicineAnimalsHumansRemacemidePharmacologyEpilepsybusiness.industryOrganic ChemistryMemantinemedicine.diseaseDizocilpineAnticonvulsantchemistryMolecular MedicineAnticonvulsantsbusinessEliprodilmedicine.drugCurrent medicinal chemistry
researchProduct

Efficacy and Safety of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Virus Infection and Inherited Blood Disorders: Final Data from the C…

2016

Abstract Background: Complications from chronic hepatitis C virus (HCV) infection are a major cause of morbidity and mortality among individuals with inherited blood disorders (IBLD). Inability to tolerate ribavirin and frequent comorbidities have limited HCV treatment options in these patients. The aim of the C-EDGE IBLD study was to evaluate the efficacy and safety of a once-daily, fixed-dose combination of elbasvir 50 mg (EBR, an NS5A inhibitor) and grazoprevir 100 mg (GZR, an NS3/4A protease inhibitor) in patients with HCV infection and IBLD, including those with hemoglobinopathies. Methods: C-EDGE-IBLD was a randomized, double-blind, placebo-controlled study of treatment-naïve and trea…

0301 basic medicineElbasvirbusiness.industryRibavirinImmunologyCell BiologyHematologyHepatitis Cmedicine.diseaseBiochemistryVirologySickle cell anemiaVirus03 medical and health scienceschemistry.chemical_compound030104 developmental biologyBlood DisorderchemistryGrazoprevirmedicineElbasvir GrazoprevirbusinessBlood
researchProduct

Evaluating the impact of roughness in soil moisture and optical thickness retrievals over the VAS area

2014

International audience

Valencia Anchor Station[SDE.MCG]Environmental Sciences/Global ChangesL - MEB modelSoil scienceSurface finishELBARA - IIsoil roughnessEnvironmental sciencesoil moistureWater content[SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processingComputingMilieux_MISCELLANEOUSRemote sensingSMOS
researchProduct

Phase III, Multicenter Open-Label Study to Investigate the Efficacy of Elbasvir and Grazoprevir Fixed-Dose Combination for Eight Weeks in Treatment-N…

2020

Background: Genotype 1b is the most common HCV genotype worldwide, accounting for the largest proportion of infections in Europe, Russia, Latin America and Asia. Reducing treatment duration can improve adherence, reduce drug exposure and cost. Accordingly, we evaluated the efficacy of eight weeks fixed dose combination of grazoprevir-elbasvir in treatment-naive patients, with non-severe fibrosis. Methods: HCV mono-infected and treatment naive patients with non-severe fibrosis (Fibroscan®<9·5kPa and Fibrotest®<0·59) were enrolled in a study which included 117 patients. Genotyping by sequencing identified five patients with non-1b genotype (two GT1a, one GT1h, one GT1e and one GT1l). Thus, we…

medicine.medical_specialtyElbasvirbusiness.industryFixed-dose combinationHepatitis Cmedicine.diseaseClinical investigatorGrazoprevirInformed consentInternal medicineGood clinical practicemedicinebusinessViral loadSSRN Electronic Journal
researchProduct